1692 related articles for article (PubMed ID: 30208379)
41. Idiopathic inflammatory myopathies: CT characteristics of interstitial lung disease and their association(s) with myositis-specific autoantibodies.
Laporte A; Mariampillai K; Allenbach Y; Pasi N; Donciu V; Toledano D; Granger B; Benveniste O; Grenier PA; Boussouar S
Eur Radiol; 2022 May; 32(5):3480-3489. PubMed ID: 35022809
[TBL] [Abstract][Full Text] [Related]
42. Clinical heterogeneity and prognostic features of South Australian patients with anti-synthetase autoantibodies.
Dugar M; Cox S; Limaye V; Blumbergs P; Roberts-Thomson PJ
Intern Med J; 2011 Sep; 41(9):674-9. PubMed ID: 20059602
[TBL] [Abstract][Full Text] [Related]
43. Statins and myotoxic effects associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase autoantibodies: an observational study in Japan.
Watanabe Y; Suzuki S; Nishimura H; Murata KY; Kurashige T; Ikawa M; Asahi M; Konishi H; Mitsuma S; Kawabata S; Suzuki N; Nishino I
Medicine (Baltimore); 2015 Jan; 94(4):e416. PubMed ID: 25634171
[TBL] [Abstract][Full Text] [Related]
44. [Pathogenesis of primary inflammatory myopathies].
Benveniste O; Squier W; Boyer O; Hilton-Jones D; Herson S
Presse Med; 2004 Nov; 33(20):1444-50. PubMed ID: 15611679
[TBL] [Abstract][Full Text] [Related]
45. Histological heterogeneity in a large clinical cohort of juvenile idiopathic inflammatory myopathy: analysis by myositis autoantibody and pathological features.
Yasin SA; Schutz PW; Deakin CT; Sag E; Varsani H; Simou S; Marshall LR; Tansley SL; McHugh NJ; Holton JL; Wedderburn LR; Jacques TS;
Neuropathol Appl Neurobiol; 2019 Aug; 45(5):495-512. PubMed ID: 30378704
[TBL] [Abstract][Full Text] [Related]
46. Paraneoplastic myopathies.
Mammen AL
Handb Clin Neurol; 2024; 200():327-332. PubMed ID: 38494286
[TBL] [Abstract][Full Text] [Related]
47. Performance of the 2017 European Alliance of Associations for Rheumatology/American College of Rheumatology Classification Criteria for Idiopathic Inflammatory Myopathies in Patients With Myositis-Specific Autoantibodies.
Casal-Dominguez M; Pinal-Fernandez I; Pak K; Huang W; Selva-O'Callaghan A; Albayda J; Casciola-Rosen L; Paik JJ; Tiniakou E; Mecoli CA; Lloyd TE; Danoff SK; Christopher-Stine L; Mammen AL
Arthritis Rheumatol; 2022 Mar; 74(3):508-517. PubMed ID: 34480833
[TBL] [Abstract][Full Text] [Related]
48. A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies.
Pinal-Fernandez I; Casal-Dominguez M; Huapaya JA; Albayda J; Paik JJ; Johnson C; Silhan L; Christopher-Stine L; Mammen AL; Danoff SK
Rheumatology (Oxford); 2017 Jun; 56(6):999-1007. PubMed ID: 28339994
[TBL] [Abstract][Full Text] [Related]
49. [The shades of anti-Jo1 positive antisynthetase syndrome in a Hungarian cohort].
Szabó K; Nagy-Vincze M; Bodoki L; Hodosi K; Dankó K; Griger Z
Orv Hetil; 2016 Apr; 157(15):575-83. PubMed ID: 27039996
[TBL] [Abstract][Full Text] [Related]
50. Myositis autoantibodies in Korean patients with inflammatory myositis: anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis.
Kang EH; Nakashima R; Mimori T; Kim J; Lee YJ; Lee EB; Song YW
BMC Musculoskelet Disord; 2010 Sep; 11():223. PubMed ID: 20875136
[TBL] [Abstract][Full Text] [Related]
51. More prominent muscle involvement in patients with dermatomyositis with anti-Mi2 autoantibodies.
Pinal-Fernandez I; Mecoli CA; Casal-Dominguez M; Pak K; Hosono Y; Huapaya J; Huang W; Albayda J; Tiniakou E; Paik JJ; Johnson C; Danoff SK; Corse AM; Christopher-Stine L; Mammen AL
Neurology; 2019 Nov; 93(19):e1768-e1777. PubMed ID: 31594859
[TBL] [Abstract][Full Text] [Related]
52. Inflammatory myopathies and systemic disorders: a review of immunopathogenetic mechanisms and clinical features.
Mantegazza R; Bernasconi P; Confalonieri P; Cornelio F
J Neurol; 1997 May; 244(5):277-87. PubMed ID: 9178151
[TBL] [Abstract][Full Text] [Related]
53. Integrated analysis of plasma and urine reveals unique metabolomic profiles in idiopathic inflammatory myopathies subtypes.
Liu D; Zhao L; Jiang Y; Li L; Guo M; Mu Y; Zhu H
J Cachexia Sarcopenia Muscle; 2022 Oct; 13(5):2456-2472. PubMed ID: 35860906
[TBL] [Abstract][Full Text] [Related]
54. [Autoantibodies of Inflammatory Myopathies: Update].
Suzuki S
Brain Nerve; 2016 Dec; 68(12):1443-1451. PubMed ID: 27916754
[TBL] [Abstract][Full Text] [Related]
55. Myositis-specific autoantibodies and their clinical associations in idiopathic inflammatory myopathies.
Wong VT; So H; Lam TT; Yip RM
Acta Neurol Scand; 2021 Feb; 143(2):131-139. PubMed ID: 32762037
[TBL] [Abstract][Full Text] [Related]
56. Autoantibodies in polymyositis and dermatomyositis.
Ghirardello A; Bassi N; Palma L; Borella E; Domeneghetti M; Punzi L; Doria A
Curr Rheumatol Rep; 2013 Jun; 15(6):335. PubMed ID: 23591825
[TBL] [Abstract][Full Text] [Related]
57. [Inflammatory myopathies: diagnosis and classifications].
Dimitri D
Presse Med; 2009; 38(7-8):1141-63. PubMed ID: 19282137
[TBL] [Abstract][Full Text] [Related]
58. Classification criteria for the idiopathic inflammatory myopathies.
Targoff IN; Miller FW; Medsger TA; Oddis CV
Curr Opin Rheumatol; 1997 Nov; 9(6):527-35. PubMed ID: 9375282
[TBL] [Abstract][Full Text] [Related]
59. [Idiopathic inflammatory myopathies].
Vencovský J
Vnitr Lek; 2018; 64(2):155-163. PubMed ID: 29595280
[TBL] [Abstract][Full Text] [Related]
60. Characteristics of idiopathic inflammatory myopathies with novel myositis-specific autoantibodies.
Rams A; Kosałka-Węgiel J; Kuszmiersz P; Matyja-Bednarczyk A; Polański S; Zaręba L; Bazan-Socha S
Adv Clin Exp Med; 2021 Dec; 30(12):1239-1248. PubMed ID: 34610217
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
